Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Idasanutlin - Roche

Drug Profile

Idasanutlin - Roche

Alternative Names: RG-7388; RO-5503781

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Mayo Clinic; National Cancer Institute (USA); NHS Greater Glasgow and Clyde; Roche; University of Glasgow
  • Class Aminobenzoic acids; Antineoplastics; Halogenated hydrocarbons; Pyrrolidines; Small molecules
  • Mechanism of Action Proto-oncogene protein c mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Solid tumours
  • Phase I/II Breast cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Multiple myeloma; Neuroblastoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer
  • Preclinical Glioblastoma; Rhabdoid tumour
  • No development reported Cancer; Essential thrombocythaemia
  • Discontinued Polycythaemia vera

Most Recent Events

  • 11 Oct 2023 Preclinical trials in Rhabdoid tumour in USA (PO) before October 2023
  • 11 Oct 2023 Pharmacodynamics data from preclinical studies in Rhabdoid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
  • 19 Jul 2023 St. Jude Children's Research Hospital plans a phase I trial for Rhabdoid-tumour (Combination therapy, Second-line or greater therapy, In Children, In Adults) in the US (PO) (NCT05952687)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top